Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Putin, Netanyahu discuss Middle East in phone call, Kremlin says - 2Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- 3Artemis II's moonbound toilet is working again to astronauts' relief after overnight fix
- 4More than half way to the moon, the Artemis II astronauts are grappling with a toilet problem
- 5Manual for Mountain Objections on the planet
- Archaeologists uncover details about the Hjortspring boat's origins
- Gov’t approves millions for border cities in North under Hezbollah fire
- This Week In Space podcast: Episode 203 — China Rising
- Russian drone slams into block of flats in deadly wave of strikes across Kyiv
- What is ‘Auld Lang Syne’? Why we sing this song at midnight on New Year’s Eve.
- These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
- IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- Chris Noth responds to backlash after seemingly shading 'Sex and the City' costar Sarah Jessica Parker: 'It is not news'
- Heat Wave Fuels Massive Wildfire In Australia
